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INTRODUCTION {#s1}
============

Typhoid fever is a poverty-related disease, with a high disease burden estimated at 14.3 million cases and approximately 200,000 deaths per year globally^[@b1]^ found disproportionately in low- and middle-income countries.^[@b2],[@b3]^ Unfortunately, the standard diagnostic test, culture of blood, is only about 50% sensitive in detecting typhoid fever,^[@b4]--[@b7]^ and there are neither reliable point-of-care diagnostic tests nor well-validated rules for defining blood culture (BC)-negative typhoid using combinations of presenting clinical signs and symptoms to guide empiric antibiotic therapy nor to permit complete evaluation of the preventive impact of typhoid vaccines.^[@b8],[@b9]^ The need for more selective targeting of patients for antibiotic therapy is underscored by growing antibiotic resistance and the need for antibiotic stewardship.^[@b10]--[@b12]^ Similarly, the need for more comprehensive assessments of prevented typhoid cases is highlighted by the advent of improved typhoid vaccines now under clinical evaluation.^[@b13]--[@b17]^

One of the challenges confronting development of non--BC-based criteria for typhoid fever is the absence of gold standard diagnostic tests for such cases. For several other invasive bacterial diseases, including invasive *Haemophilus influenzae* type b and *Streptococcus pneumoniae*, vaccine probe studies have been used to define pathogen-attributable disease syndromes in which cultures of normally sterile fluids are negative.^[@b18]--[@b22]^ The probe design, which relies on detecting vaccine efficacy against these culture-negative clinical syndromes, can produce an estimate of the aetiological fraction of a disease syndrome because of the pathogen targeted by vaccine, effectively overcoming challenges in diagnostic insensitivity.^[@b22]^ However, this approach only works when a clinical syndrome can be defined for which the proportion of culture-negative disease caused by the target pathogen is sufficiently high. If low, measured vaccine protection will be "washed out" by cases not caused by the target pathogen.

In an earlier cluster-randomized trial (CRT) of typhoid Vi-polysaccharide (ViPS) vaccine, it was possible to detect both direct and herd protection of Vi against BC-proven typhoid.^[@b23]^ However, it was not possible to detect significant Vi protection, either direct or herd, against BC-negative cases presenting with fever of at least 3 days duration, suggesting that we needed more specific clinical criteria for defining the target syndrome than prolonged fever per se. However, we lacked these clinical criteria. In this article, we present a novel approach for defining clinical criteria for culture-negative, clinical typhoid leveraging a vaccine probe analysis within the earlier CRT of the ViPS vaccine.

METHODS AND MATERIALS {#s2}
=====================

General approach.
-----------------

We reanalyzed a CRT of ViPS vaccine launched in 2004, as well as 2 years of antecedent typhoid surveillance in the vaccine trial population, in urban slums in Kolkata, India.^[@b23]^ To derive an empirically validated clinical rule for BC-negative, clinical typhoid fever, we required that three conditions be met: 1) the clinical features for the rule should also discriminate between episodes of prolonged fever that are BC positive for *S.* Typhi and those that are negative for *S.* Typhi, 2) the diagnostic specificity of the rule should yield a number of BC-negative clinical typhoid episodes approximately equal to the number of BC-positive episodes in the same population (because BCs are known to be about 50% sensitive in detected typhoid fever),^[@b24]--[@b28]^ and 3) a rule meeting the first two conditions should identify BC-negative episodes against which there was detectable vaccine efficacy by ViPS vaccine in the CRT, thereby using ViPS vaccine as a probe. To derive a clinical rule with the desired level of diagnostic specificity, we used recursive partitioning, a classification algorithm that considers candidate individual variables for the rule conjointly to arrive at a rule with desired levels of specificity and sensitivity.^[@b29]^ This approach has several advantages over other machine learning classification algorithms, namely, that it produces an easily visualized decision tree allowing for simplistic interpretation of subject classification.

The ViPS vaccine trial in Kolkata.
----------------------------------

The study was conducted in an urban slum site in Kolkata city, the capital of West Bengal, India. The Kolkata Municipal Corporation area had an estimated population of six million at the time of the trial. A census of 66,458 people was conducted 2 years before the onset of the trial. Individual- and household-level demographic and socioeconomic data were subsequently updated at regular intervals in a demographic surveillance system that continued through the vaccine trial. A close-out census was carried out at the end of surveillance, 2 years after vaccination. Typhoid fever surveillance was carried out in the study population during a 2-year lead-in period before vaccination and continued for 2 years following vaccination. Subjects from the study area who presented at one of five study clinics with a history of fever for at least 3 days were enrolled by a study physician. Subjects' clinical histories and physical findings were systematically captured during enrollment. After obtaining verbal informed consent, a 5-mL blood specimen was collected by venipuncture for microbiological culture using an automated system (Becton Dickinson, Franklin Lakes, NJ) and bacterial identification through conventional biochemical and serologic methods.^[@b30]^ The CRT was initiated in 2004. Residents aged 2 years and older in 80 clusters were randomly allocated at a one-to-one ratio to Vi vaccine (Typherix, GlaxoSmithKline, Brentford, United Kingdom) or inactivated hepatitis A (HepA) vaccine (Havrix, GlaxoSmithKline). A total of 18,869 participants received Vi vaccine, and 18,804 received HepA vaccine. After 2 years of surveillance, the total Vi-vaccine protection against typhoid fever (comparing the incidence of typhoid in Vi vaccinees versus HepA vaccinees) was 61%; indirect protection (comparing the incidence of typhoid in non-vaccinees in the Vi clusters versus non-vaccinees in the HepA clusters) and overall protection (comparing the incidence of typhoid in all members of the Vi clusters versus all members of the HepA clusters) were 44% and 57%, respectively.^[@b23]^

Definition and assembly of prolonged fever episodes for analysis.
-----------------------------------------------------------------

We assembled all prolonged febrile episodes from the surveillance leading up to and during the cluster-randomized trial. A febrile visit was defined as an individual visit by a study area resident to a study clinic presenting with a history of fever for at least 3 days. A febrile episode was defined as all component febrile visits in which the onset of symptoms for a subsequent visit was less than 14 days from the date of discharge for the previous visit. A BC-proven typhoid episode was considered to be a febrile episode in which *Salmonella enterica* serovar Typhi (*S.* Typhi) was isolated from at least one BC. For this analysis, where multiple fever visits comprised a febrile episode, we considered the date of onset of illness to be the date of onset of symptoms for the first component visit of the episode. From these episodes, analysis included individuals for whom data for all clinical parameters under consideration (vide infra) were available ([Figure 1](#f1){ref-type="fig"}).

![Flow diagram showing culture-confirmed typhoid fever in Vi and HepA clusters.](tpmd190968f1){#f1}

Statistical analysis.
---------------------

We used a machine learning algorithm to create a decision tree constructed via binary recursive partitioning.^[@b31]^ The decision tree was designed to predict whether a febrile episode was culture-positive typhoid fever, using 22 clinical signs and symptoms and epidemiological characteristics recorded at the time of initial presentation for care for the episode. Each sign and symptom was first converted into a dichotomous variable. For the machine learning modeling, we selected as candidate variables only those that had an association with typhoid with *P*-value ≤ 0.25 in bivariate logistic regression analyses.

Because predictive rules may overestimate predictive performance when tested on the data used to derive the rules, we split all individuals who resided in the study area during the 4 years of follow-up, at random, into two approximately equal-sized groups, for development (training dataset) and validation (validation dataset) of the clinical predictive rule, respectively. For development and testing of the rule, we considered all febrile episodes of all patients presenting with at least 3 days of fever in the training and validation groups for whom complete clinical data were available. We initially ran the recursive partitioning algorithm for candidate clinical predictive variables in the training set episodes, specifying an alternative loss function that penalized a false-negative prediction 10 times more heavily than a false-positive prediction. Because of unbalanced class data, we set the minimum number of observations as 30 for the nonterminal nodes of the decision tree and 10 for the terminal nodes of the decision tree. For cross-validation, the training set was randomly partitioned into 10 parts, one part was used in estimating cross-validation error.^[@b32]^

For these analyses of the training dataset, we constructed trees at several different levels, choosing the tree with the lowest level, and thus the simplest clinical algorithm, that still met our three performance criteria (vide supra). To find the optimal tree in the training set, the model was pruned by the minimal complexity parameter corresponding to minimum error with at least five tree rules. We constructed a receiver operating characteristic (ROC) curve for the selected rule, evaluating the area under the ROC curve as described elsewhere,^[@b33],[@b34]^ and also used the curve to identify a cutoff probability that corresponded to the highest sensitivity for cutoffs, giving 97--98% specificity. To measure the protective efficacy (PE) of ViPS vaccine against culture-negative typhoid, we contrasted ViPS vaccine recipients with HepA vaccine recipients for the occurrence of all episodes of culture-negative fever meeting the criteria of the clinical prediction rule, using the Andersen--Gill (AG) generalized Cox proportional hazard regression model after verifying that the proportionality assumptions were fulfilled.^[@b35]^ The model was adjusted for age of the individual and living in a household that used a designated place for waste disposal. The hazard ratio (HR) for culture-negative typhoid fever was estimated by exponentiation of the coefficient of receipt of ViPS in the model, and the 95% CI for the HR was estimated using a robust sandwich method. The protective effectiveness (PE) of ViPS vaccination against BC-negative typhoid fever defined by our clinical rule was estimated as (1-HR) × 100%. We considered *P* \< 0.05 (two-tailed) as the margin of statistical significance. The analysis was performed using "rpart" package for decision tree modeling, "caTools" for random selection, "rpart.plot" package for tree plotting, "pROC" packages for ROC curve,^[@b36]^ "survival" for AG Cox model,^[@b37]^ and "dplyr" package for data management under R-Studio.^[@b38]^ Once having conducted these developmental analyses in the training dataset, we assessed the sensitivity and specificity of the rule in predicting BC-positive typhoid fever and in defining a BC-negative syndrome against which ViPS protected in the validation dataset.

RESULTS {#s3}
=======

From March 2003 to January 2007, a total population of 70,865 individuals was included in the surveillance. During vaccination, which took place between November 2004 and December 2004, 67,163 age-eligible individuals were randomized to receive either ViPS vaccine (18,869 vaccinated) or HepA vaccine (18,804 vaccinated) ([Figure 1](#f1){ref-type="fig"}). Total protection by ViPS was 61% (95% CI: 41--75; *P* \< 0.001); complete results of the vaccine trial have been reported previously.^[@b23]^ A total of 14,905 febrile visits, comprising 14,797 fever episodes, in 11,255 individuals were observed between March 19, 2003 and January 28, 2007, from which 323 BC-proven typhoid cases were recorded. For our analysis, 515 fever episodes, including nine typhoid cases, were excluded due to incompatibility with fever criterion (i.e., fever duration less than 3 days) or incomplete clinical metadata ([Figure 1](#f1){ref-type="fig"}). We included 14,282 fever episodes and 314 BC-proven typhoid cases in the analysis. From bivariate logistic regression analysis, 17 of 22 recorded clinical and epidemiological features had a significant association (*P*-value ≤ 0.25) with confirmed typhoid. These include age \< 15 years, typhoid season (April to June and September to November), high temperature (≥ 100°F by axillary measurement), abdominal pain, constipation, dehydration, diarrhea, abdominal distension, drowsiness, headache, nausea, palpable liver, palpable spleen, abdominal tenderness, heart rate \> 80/minute, thirst, and vomiting ([Table 1](#t1){ref-type="table"}). Blood culture--confirmed typhoid was not observed among individuals exhibiting abdominal peritoneal signs or seizure.

###### 

Bivariate relationships[\*](#t1fn1){ref-type="table-fn"} between candidate clinical and epidemiological features and typhoid fever

  Feature                                                      Culture-negative fever episode (*n* = 13,968), *n* (%)   Culture-positive typhoid fever episode (*n* = 314), *n* (%)   *P*-value
  ------------------------------------------------------------ -------------------------------------------------------- ------------------------------------------------------------- -----------
  Age (\< 15 years)[†](#fn1){ref-type="author-notes"}          4,742 (33.9)                                             191 (60.8)                                                    \< 0.001
  Gender (male)                                                7,180 (52.1)                                             159 (51.8)                                                    0.919
  Typhoid season[‡](#fn1){ref-type="author-notes"}             7,573 (54.2)                                             201 (64.0)                                                    0.001
  Fever duration (\> 7 days)[§](#t1fn2){ref-type="table-fn"}   1,238 (8.9)                                              28 (8.9)                                                      0.973
  High temperature (≥ 100°F)[‖](#t1fn3){ref-type="table-fn"}   7,012 (50.2)                                             205 (65.3)                                                    \< 0.001
  Abdominal pain                                               1,711 (12.2)                                             71 (22.6)                                                     \< 0.001
  Constipation                                                 1,752 (12.5)                                             47 (15.0)                                                     0.201
  Dehydration                                                  13,134 (94)                                              284 (90.4)                                                    0.009
  Diarrhea                                                     374 (2.7)                                                12 (3.8)                                                      0.219
  Abdominal distension                                         709 (5.1)                                                24 (7.6)                                                      0.043
  Drowsiness                                                   110 (0.8)                                                8 (2.5)                                                       0.001
  Headache                                                     8,015 (57.4)                                             195 (62.1)                                                    0.095
  Ileus sign                                                   5 (0)                                                    0 (0)                                                         0.967
  Nausea                                                       3,312 (23.7)                                             95 (30.3)                                                     0.007
  Palpable liver                                               577 (4.1)                                                22 (7)                                                        0.013
  Peritoneal signs                                             6 (0)                                                    0 (0)                                                         0.964
  Seizure                                                      19 (0.1)                                                 0 (0)                                                         0.972
  Palpable spleen                                              267 (1.9)                                                9 (2.9)                                                       0.228
  Abdominal tenderness                                         1,079 (7.7)                                              36 (11.5)                                                     0.015
  Heart rate (\> 80 bpm)                                       12,054 (86.3)                                            299 (95.2)                                                    \< 0.001
  Thirsty                                                      3,455 (24.7)                                             117 (37.3)                                                    \< 0.001
  Vomiting                                                     1,341 (9.6)                                              42 (13.4)                                                     0.026

Assessed with logistic regression.

† Age was considered at the date of fever onset.

‡ Typhoid seasons defined as April to June and September to November.

By reported clinical history.

Axillary, oral, or rectal temperature measurement.

Assembly of training and validation datasets.
---------------------------------------------

In the training dataset, 7,195 febrile episodes in 5,462 individuals were randomly selected. Among these episodes, 1,748 and 1,799 episodes were from ViPS vaccine and HepA vaccine recipients, respectively, occurred after vaccination. The rest of the episodes were from the nonparticipants in the trial. Similarly, 7,087 febrile episodes from the 5,462 individuals were randomly selected for the validation set, of which 1,683 and 1,767 episodes were from ViPS vaccine and HepA vaccine recipients, respectively, occurred after vaccination ([Table 2](#t2){ref-type="table"}).

###### 

Population assembly for training and validation sets

                   Population           Full study period   Before vaccination   After vaccination                           
  ---------------- -------------------- ------------------- -------------------- ------------------- ------- ------- ------- -----
  Full set         Before vaccination   3,702               102                  4                   102     4               
  Vi cluster       Vaccinated           18,869              5,438                91                  2,007   55      3,431   36
  Not vaccinated   14,449               1,459               26                   479                 8       980     18      
  HepA cluster     HepA vaccinated      18,804              5,639                147                 2,073   48      3,566   99
  Not vaccinated   15,041               1,644               46                   529                 14      1,115   32      
                   Total                70,865              14,282 (10,924)      314                 5,190   129     9,092   185
  Training set     Before vaccination   1,851               56                   2                   56      2               
  Vi cluster       Vaccinated           9,436               2,752                41                  1,004   21      1,748   20
  Not vaccinated   7,197                732                 11                   217                 4       515     7       
  HepA cluster     HepA vaccinated      9,404               2,846                77                  1,047   31      1,799   46
  Not vaccinated   7,540                809                 26                   257                 11      552     15      
                   Total                35,428              7,195 (5,462)        157                 2,581   69      4,614   88
  Validation set   Before vaccination   1,851               46                   2                   46      2               
  Vi cluster       Vi vaccinated        9,433               2,686                50                  1,003   34      1,683   16
  Not vaccinated   7,252                707                 13                   262                 4       465     11      
  HepA cluster     HepA vaccinated      9,400               2,793                70                  1,026   17      1,767   53
  Not vaccinated   7,501                816                 20                   272                 3       563     17      
                   Total                35,437              7,087 (5,462)        157                 2,609   60      4,478   97

Note: For randomized individuals who did not receive a vaccine, vaccine date was set as the median date of vaccination of vaccinees in the cluster of residence.

Analysis of training dataset.
-----------------------------

The training set was used to build a training model to predict BC-proven typhoid. The model was tuned by varying cutoff probabilities starting from 0% to 50% incremented by 1% using the grid-search technique,^[@b39]^ and the predefined specificity (97--98%) was matched at 6--10% cutoff probabilities. A decision tree with a depth of four was selected as the optimal model because it was able to provide a sufficiently simple rule for clinical diagnosis and yielded specified probability cutoff range of 9%. We derived the following rules for defining BC-proven typhoid in the population ([Figure 2](#f2){ref-type="fig"}).

![Depth four decision tree specifying clinical and epidemiological criteria for prediction of blood culture--positive typhoid. Note: Prediction (represented by terminal node) cutoff probability (P) is set as 0.09. † Age was considered at date of fever onset. ‡ Axillary, oral, or rectal temperature measurement.](tpmd190968f2){#f2}

Rule 1: patients aged \< 15 years with high temperature (≥ 100°F), headache, and nausea.

Rule 2: patients aged ≥ 15 years with nausea, palpable liver, and without constipation.

Overall, the accuracy of the training model was 95%, with 16% sensitivity and 97% specificity, and the area under curve (AUC) showed significant difference from the 50% random line, measured as 69% (95% CI: 65--73) ([Figure 3](#f3){ref-type="fig"}). When these criteria were used to define BC-negative syndromes, the adjusted PE of the ViPS vaccine was 31% (95% CI: 2--52, *P* = 0.040) for all age-groups ([Table 3](#t3){ref-type="table"}). Evaluations of the validation dataset yielded similar results. Overall, the accuracy of the validation model was 95%, with 97% specificity. The sensitivity of the model decreased from 16.0% to 7.0%; however, the AUC from the ROC curve remained significant at 65% (95% CI: 61--70) ([Figure 3](#f3){ref-type="fig"}). The vaccine PE of ViPS vaccine against BC-negative syndromes meeting the derived clinical criteria in the validation set was 33% (95% CI: 4--53, *P* = 0.027) for all age-groups. By comparison, the PE of ViPS vaccine against all fever episodes was 0% (95% CI: −7 to 7) and 1% (95% CI: −6 to 8) in the training and validation datasets, respectively ([Supplemental Table 1](/content/journals/10.4269/ajtmh.19-0968#supplementary_data)).

![Receiver operating characteristic curve for different cutoff values for defining typhoid in the training and validation datasets. AUC = area under the curve. This figure appears in color at [www.ajtmh.org](http://www.ajtmh.org).](tpmd190968f3){#f3}

###### 

Protective effectiveness of Vi-polysaccharide vaccine against clinical typhoid as defined by rules 1 and 2

                      Vi vaccine group   HepA vaccine group   Protective effectiveness (PE)   *P*-value                                                                                                         
  ------------------- ------------------ -------------------- ------------------------------- ----------- ------- ---- -------- ------- --------------- ------- ----------------------------------------------- -------
  Training set                                                                                                                                                                                                  
   All ages (years)   9,436              51                   18,345                          278         9,404   77   18,266   422     34 (6, 54)      0.021   31 (2, 52)[†](#t3fn2){ref-type="table-fn"}      0.040
   2--14              2,657              49                   5,143                           953         2,847   74   5,511    1,343   29 (−2, 51)     0.062   29 (−2, 50)[‡](#t3fn3){ref-type="table-fn"}     0.063
   ≥ 15               6,779              2                    13,202                          15          6,557   3    12,754   24      36 (−285, 89)   0.630   36 (−285, 89)[‡](#t3fn3){ref-type="table-fn"}   0.630
  Validation set                                                                                                                                                                                                
   All ages (years)   9,433              52                   18,320                          284         9,400   79   18,242   433     34 (7, 54)      0.018   33 (4, 53)[†](#t3fn2){ref-type="table-fn"}      0.027
   2--14              2,722              49                   5,284                           927         2,832   75   5,486    1,367   32 (3, 53)      0.035   32 (3, 53)[‡](#t3fn3){ref-type="table-fn"}      0.033
   ≥ 15               6,711              3                    13,035                          23          6,568   4    12,756   31      27 (−227, 84)   0.684   27 (−227, 84)[‡](#t3fn3){ref-type="table-fn"}   0.684

IR = incidence rate; PE= (1−HR) ×100; PY = person-years. Age at date of vaccination.

Based on clinical typhoid end point, defined as either rule 1 (patients aged \< 15 years with high temperature (≥ 100°F), headache, and nausea) or rule 2 (patients aged ≥ 15 years with nausea, palpable liver, and without constipation).

Protective effectiveness is adjusted for age and individual living in a household using a specific place for waste disposal.

Protective effectiveness is adjusted for individual living in a household using a specific place for waste disposal.

DISCUSSION {#s4}
==========

Our analysis demonstrates that it is possible to use clinical, demographic, and epidemiological variables to describe a clinical syndrome for typhoid in a manner which maintains acceptable diagnostic specificity for BC-proven typhoid, yielding a plausible number of clinical typhoid cases in the BC-negative group, and demarcates a group of BC-negative, persistent febrile episodes against which ViPS vaccine protects. We believe that this is the first time that an effective typhoid vaccine has been used as a "probe" to test the validity of clinical criteria for clinical typhoid.

Several studies have investigated the clinical symptoms predictive of proven typhoid fever, although these studies assessed disparate populations and age-groups, include varying ranges of clinical factors, and used different methods to substantiate their findings. Despite this heterogeneity, several notable variables are stated to have a high positive predictive value for culture-confirmed typhoid or to be statistically associated with culture-confirmed typhoid by logistic regression across multiple studies. These clinical variables include fever,^[@b40]--[@b44]^ relative bradycardia,^[@b45]--[@b47]^ coated tongue,^[@b46],[@b47]^ positive Widal test,^[@b44],[@b47]^ vomiting,^[@b40]--[@b43]^ diarrhea,^[@b40]--[@b43]^ palpable spleen,^[@b40]--[@b44]^ and palpable liver.^[@b42]--[@b44],[@b48]^ A clinical trial of ViPS vaccine in Nepal identified culture-negative patients with clinical suspicion of typhoid fever (defined as prolonged fever of three consecutive days, heart rate ≤ 80 beats per minute, and palpable spleen) for whom ViPS vaccine was 80% efficacious; however, specificity or sensitivity of these criteria was not reported.^[@b49]^ When we examined these criteria from the Nepal trial for culture-negative typhoid in our data, we found that there were four episodes in HepA vaccinees versus zero episodes in ViPS recipients. To our knowledge, this is the first study to offer a validated clinical predictor rule to diagnose typhoid using clinical data.

Our findings should be interpreted in light of several important limitations. First, reporting of clinical signs and symptoms may have suffered from errors due to limitations in the accuracies of medical histories provided by patients and the examinations performed by clinicians under hectic outpatient clinic conditions in crowded study facilities in urban slums. However, our findings do provide a realistic picture of diagnostic rules that can be used in such settings, which are common in typhoid-endemic populations in the developing world. Second, we did not consider point-of-care diagnostic laboratory results, as these were not uniformly available at the time of presentation in the clinics. Again, the absence of availability of such data for clinical decision-making at the time of patient presentation may be the rule, not the exception, in typhoid-endemic settings. Third, we did not include any post-presentation clinical information---which would not be applicable to the needs of clinicians making decisions on initial presentation of febrile patients, but might be of interest for other purposes, such as classifying BC-negative typhoid end points for a typhoid vaccine efficacy trial. Fourth, our analysis contained a mix of vaccinated and unvaccinated febrile patients. In future analyses, we will consider the applicability of our clinical prediction rule to these two types of patients separately. Fifth, it is possible that our findings are idiosyncratic to the population and epidemiological setting for the study. Further assessments in disparate populations are required to determine whether clinical predictors might be generalizable from one setting to another. Finally, the level of protective effectiveness observed in the Vi probe analysis in the training and validation sets, although statistically significant and consistent between the two sets, was lower than the 61% protection by Vi against BC-proven typhoid in the Kolkata trial. This could mean that our rules for clinical typhoid were insufficiently specific and that Vi protection is indeed lower against BC-negative typhoid fever, or both.

However, several considerations strengthen our findings. First, the study was a large, prospective, population-based cohort, comprehensively followed and systematically evaluated for febrile episodes and for typhoid using well-validated microbiological methods in experienced clinical laboratories. Second, the accumulated data were sufficient in size to make use of independent cohorts to both derive and test the clinical prediction rule. Moreover, validation of the derived rule was strengthened by demanding high diagnostic specificity and using the results of a vaccine probe analysis. Finally, vaccine protection against all persistent fever episodes was not detected, demonstrating the discriminatory value of our predictive rule.

In the absence of a sensitive typhoid point-of-care diagnostic, a reliable and highly specific clinical rule for predicting typhoid, irrespective of culture positivity, will be useful to guide healthcare workers practicing in endemic, low-resource settings.^[@b50]^ With a new series of phase III and IV trials being undertaken in Bangladesh, Nepal, and Malawi to evaluate new generation, Vi-protein conjugate vaccines,^[@b16],[@b51]--[@b53]^ our vaccine probe approach should be considered in future analyses to confirm and extend our findings.

Supplemental table
==================

[Supplemental materials](/content/journals/10.4269/ajtmh.19-0968#supplementary_data)
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